Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy?
Cytokines are small proteins that regulate the growth and functional activity of immune cells, and several have been approved for cancer therapy. Oncolytic viruses are agents that mediate antitumor activity by directly killing tumor cells and inducing immune responses. Talimogene laherparepvec is an...
Saved in:
Main Authors: | Howard L Kaufman, Hongbin Wang, Dipongkor Saha, Samuel D Rabkin, Mia Borlongan, Uyen Le, Hans J Nauwynck |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-05-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/12/5/e008025.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Preclinical Evaluation of Oncolytic Δγ134.5 Herpes Simplex Virus Expressing Interleukin-12 for Therapy of Breast Cancer Brain Metastases
by: James J. Cody, et al.
Published: (2012-01-01) -
Oncolytic immunotherapy: multiple mechanisms of oncolytic peptides to confer anticancer immunity
by: Xing Huang, et al.
Published: (2022-07-01) -
An Unusual Psychiatric Emergency: Herpes Simplex Encephalitis
by: H. Doyle, et al.
Published: (1994-01-01) -
Mucosal Herpes Immunity and Immunopathology to Ocular and Genital Herpes Simplex Virus Infections
by: Aziz Alami Chentoufi, et al.
Published: (2012-01-01) -
Oncolytic Immunotherapy: Where Are We Clinically?
by: Akseli Hemminki
Published: (2014-01-01)